Literature DB >> 27484659

Paroxysmal Supraventricular Tachycardia: Pathophysiology, Diagnosis, and Management.

Salah S Al-Zaiti1, Kathy S Magdic2.   

Abstract

Paroxysmal supraventricular tachycardia (PSVT) is a well-known and thoroughly studied clinical syndrome, characterized by regular tachycardia rhythm with sudden onset and abrupt termination. Most patients present with palpitations and dizziness, and their electrocardiogram demonstrates a narrow QRS complex and regular tachycardia with hidden or inverted P waves. PSVT is caused by re-entry due to the presence of inhomogeneous, accessory, or concealed conducting pathways. Hemodynamically stable patients are treated by vagal maneuvers, intravenous adenosine, diltiazem, or verapamil, hemodynamically unstable patients are treated by cardioversion. Patients with symptomatic and recurrent PSVT can be treated with long-term drug treatment or catheter ablation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Accessory pathways; Paroxysmal supraventricular tachycardia; Supraventricular arrhythmia; Wolff-Parkinson-White syndrome

Mesh:

Substances:

Year:  2016        PMID: 27484659     DOI: 10.1016/j.cnc.2016.04.005

Source DB:  PubMed          Journal:  Crit Care Nurs Clin North Am        ISSN: 0899-5885            Impact factor:   1.326


  9 in total

1.  Emergency department visits for paroxysmal supraventricular tachycardia in Saudi Arabia.

Authors:  Saqer M Althunayyan; Anas A Khan; Osama A Samarkandi
Journal:  Saudi J Anaesth       Date:  2018 Oct-Dec

2.  Impact of Radiofrequency Ablation and Antiarrhythmic Medications on the Quality of Life of Patients with Supraventricular Tachycardias: Preliminary Validation of the Greek Version of the Umea22 (U22) Questionnaire.

Authors:  Philippe-Richard Domeyer; Smaragda Ch Giannakidou; Panagiota Kyriakou; Vasiliki Katsari; Antonios P Antoniadis; Ioannis K Lagos; Nikolaos Fragakis; Agoritsa Varaklioti; Vassilios P Vassilikos
Journal:  Biomed Res Int       Date:  2018-10-09       Impact factor: 3.411

3.  Paroxysmal supraventricular tachycardia and risk of ischemic stroke: A systematic review and meta-analysis.

Authors:  Pongprueth Rujirachun; Phuuwadith Wattanachayakul; Arjbordin Winijkul; Patompong Ungprasert
Journal:  J Arrhythm       Date:  2019-05-14

4.  Efficacy and economic benefits of a modified Valsalva maneuver in patients with paroxysmal supraventricular tachycardia.

Authors:  Wei Wang; Teng-Fei Jiang; Wei-Zhong Han; Lin Jin; Xiao-Jing Zhao; Ying Guo
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

5.  Prehospital conversion of paroxysmal supraventricular tachycardia using the modified Valsalva maneuver: A case report.

Authors:  Padarath Gangaram; Yugan Pillay; Bernard Christopher Pillay; Guillaume Alinier
Journal:  Qatar Med J       Date:  2020-11-27

6.  Valsalva maneuver using a Handmade Device in Supraventricular Tachycardia Reversion; a Quasi Experimental Study.

Authors:  Maryam Motamedi; Mohammad Ali Akbarzadeh; Saeed Safari; Mehrnoosh Shahhoseini
Journal:  Emerg (Tehran)       Date:  2017-10-15

7.  Therapeutic effect of radiofrequency ablation on children with supraventricular tachycardia and the risk factors for postoperative recurrence.

Authors:  Chunli Li; Libo Jia; Zhenzhou Wang; Ling Niu; Xinjiang An
Journal:  Exp Ther Med       Date:  2018-03-22       Impact factor: 2.447

8.  Head Down Deep Breathing for Cardioversion of Paroxysmal Supraventricular Tachycardia.

Authors:  Steven Hoon Chin Lim; Shieh Mei Lai; Kelvin Cheok Keng Wong
Journal:  Case Rep Emerg Med       Date:  2018-09-23

Review 9.  Therapeutic Potential of Highly Selective A3 Adenosine Receptor Ligands in the Central and Peripheral Nervous System.

Authors:  Elisabetta Coppi; Federica Cherchi; Martina Venturini; Elena Lucarini; Renato Corradetti; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Felicita Pedata; Anna Maria Pugliese
Journal:  Molecules       Date:  2022-03-15       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.